Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3

March 3, 2023

https://www.globenewswire.com/news-release/2023/03/03/2620156/0/en/Praxis-Precision-Medicines-Announces-Topline-Results-from-the-Essential1-Study-of-Ulixacaltamide-for-the-Treatment-of-Essential-Tremor-and-Continued-Advancement-of-Program-to-Phase.html

Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in an end of Phase 2 meeting and initiate a ulixacaltamide Phase 3 study for the treatment of essential tremor in 2H23

Read more at globenewswire.com

Related news for (PRAX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.